RIGL R&D to Revenue
Rigel Pharmaceuticals Inc · R&D to Revenue
RIGL R&D to Revenue
Latest reported17.74%period ending
RIGL Quarterly R&D/Revenue (0.00% → 17.74%)
Latest values, visible window
High-resolution chart · PNG
RIGL r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 17.7388% | |
| 19.8511% | |
| 15.3076% | |
| 10.5856% | |
| 6.708% | |
| 15.8176% | |
| 9.7785% | |
| 11.1776% | |
| 15.0376% | |
| 20.4036% | |
| 8.9014% | |
| 23.0149% | |
| 17.749% | |
| 38.6997% | |
| 29.9641% | |
| 65.444% | |
| 49.5221% | |
| 92.4649% | |
| 65.1869% | |
| 84.9464% | |
| 63.9877% | |
| 20.7682% | |
| 82.0488% | |
| 79.3953% | |
| 88.7211% | |
| 28.9611% | |
| 92.513% | |
| 69.3436% | |
| 127.0875% | |
| 86.7316% | |
| 36.3658% | |
| 228.0987% | |
| 604.197% | |
| 0% | |
| 0% | |
| 1,200.8889% | |
| 0% | |
| 345.3125% | |
| 387.8% | |
| 430.0798% | |
| 203.2581% | |
| 361.3641% | |
| 194.0143% | |
| 119.2752% | |
| 290.49% | |
| 720.9366% | |
| 177.1273% | |
| 0% | |
| 0% | |
| 0% | |
| 313.8435% | |
| 0% | |
| 1,385.2143% | |
| 0% | |
| 0% | |
| 0% | |
| 1,394.9333% | |
| 2,387.2% | |
| 0% | |
| 397.6119% | |
| 4,331.3924% | |
| 0% | |
| -11.0064% | |
| 22.6806% | |
| 33.9992% | |
| 534.3453% | |
| 2,690% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 274.5% | |
| 0% | |
| 878.7832% | |
| 599.2057% | |
| 479.6036% | |
| 229.3129% | |
| 92.2072% | |
| 148.641% | |
| 222.2924% | |
| 416.6971% | |
| 299.7612% | |
| 426.7762% | |
| 1,117.7273% | |
| 2,013.0501% | |
| 757.7673% | |
| 786.4156% | |
| 553.9411% | |
| 522.5392% | |
| 455.4278% | |
| 222.5928% | |
| 258.6216% | |
| 318.2042% | |
| 278.2107% | |
| 246.2421% | |
| 186.6081% | |
| 205.2068% |